Antioxidant studies of chitosan nanoparticles containing naringenin and their cytotoxicity effects in lung cancer cells

International Journal of Biological Macromolecules

Volumn 78, Issue , 2015, Pages 87-95

  Kumar, Sekar Praveen ^a   Birundha, Kannan ^a   Kaveri, Kannan ^a   Devi, K T Ramya ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Chitosan; Lung cancer cells; Nanoparticles; Naringenin

Indexed keywords

CHITOSAN NANOPARTICLE; NARINGENIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CHITOSAN; FLAVANONE DERIVATIVE; NANOPARTICLE;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; ENCAPSULATION; FIBROBLAST; FREE RADICAL SCAVENGING ASSAY; HUMAN; HUMAN CELL; LUNG CANCER; PARTICLE SIZE; STOMACH JUICE; ANIMAL; CHEMISTRY; DRUG FORMULATION; INFRARED SPECTROSCOPY; LUNG TUMOR; MOUSE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; CHITOSAN; DRUG COMPOUNDING; DRUG LIBERATION; FLAVANONES; HUMANS; LUNG NEOPLASMS; MICE; NANOPARTICLES; PARTICLE SIZE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84927744021     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.03.045     Document Type: Article

References (54)

1. Lodhi G., Kim Y-S., Hwang J-W., Kim S-K., Jeon Y-J., Je J-Y., et al. Chitooligosaccharide and its derivatives: preparation and biological applications. BioMed Res. Int. 2014, 2014:654913.
2. Ghaz-Jahanian M.A., Abbaspour-Aghdam F., Anarjan N., Berenjian A., Jafarizadeh-Malmiri H. Application of chitosan-based nanocarriers in tumor-targeted drug delivery. Mol. Biotechnol. 2014, 57:201-208.
3. Katas H., Raja M.A.G., Lam K.L. Development of chitosan nanoparticles as a stable drug delivery system for protein/siRNA. Int. J. Biomater. 2013, 2013:146320.
4. Madhumathi K., Binulal N.S., Nagahama H., Tamura H., Shalumon K.T., Selvamurugan N., et al. Preparation and characterization of novel beta-chitin-hydroxyapatite composite membranes for tissue engineering applications. Int. J. Biol. Macromol. 2009, 44(1):1-5.
5. Jayakumar R., Prabaharan M., Sudheesh Kumar P.T., Nair S.V., Furuike T., Tamur H. Novel chitin and chitosan materials in wound dressing. Biomedical Engineering, Trends in Materials Science [Internet] 2011, InTech, Available from: 〈http://www.intechopen.com/books/biomedical-engineering-trends-in-materials-science/novel-chitin-and-chitosan-materials-in-wound-dressing〉 [cited 2014 Nov 7]. A. Laskovski (Ed.).
6. Sandri G., Bonferoni M.C., Ferrari F., Rossi S., Mori M., Caramella C. Opportunities offered by chitosan-based nanotechnology in mucosal/skin drug delivery. Curr. Top. Med. Chem. 2015, 12:401-412.
7. Cascone M.G., Pot P.M., Lazzeri L., Zhu Z. Release of dexamethasone from PLGA nanoparticles entrapped into dextran/poly(vinyl alcohol) hydrogels. J. Mater. Sci. Mater. Med. 2002, 13(3):265-269.
8. Pescina S., Sonvico F., Santi P., Nicoli S. Therapeutics and carriers the dual role of proteins in nanoparticles for ocular delivery. Curr. Top. Med. Chem. 2015, 17:369-385.
9. Saranya N., Moorthi A., Saravanan S., Devi M.P., Selvamurugan N. Chitosan and its derivatives for gene delivery. Int. J. Biol. Macromol. 2011, 48(Mar (2)):234-238.
10. Mango R., Vecchione L., Raso B., Borgiani P., Brunetti E., Mehta J.L., et al. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opin. Pharmacother. 2005, 6(Dec (15)):2565-2576.
11. Lee H-W., Park Y-S., Jung J-S., Shin W-S. Chitosan oligosaccharides, dp 2-8, have prebiotic effect on the Bifidobacterium bifidium and Lactobacillus sp. Anaerobe 2002, 8(Dec (6)):319-324.
12. Mi Y., Bakker E. Determination of complex formation constants of lipophilic neutral ionophores in solvent polymeric membranes with segmented sandwich membranes. Anal. Chem. 1999, 71(Dec (23)):5279-5287.
13. Otto K., Elwing H., Hermansson M. Effect of ionic strength on initial interactions of Escherichia coli with surfaces, studied on-line by a novel quartz crystal microbalance technique. J. Bacteriol. 1999, 181(Sep (17)):5210-5218.
14. Calvo P., Remuñan-López C., Vila-Jato J.L., Alonso M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 1997, 14(10):1431-1436.
15. Shu X.Z., Zhu K.J. A novel approach to prepare tripolyphoshate/chitosan complex beads for controlled release drug delivery. Int. J. Pharm. 2000, 201(May (1)):51-58.
16. Trachootham D., Lu W., Ogasawara M.A., Nilsa R-D.V., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10(8):1343-1374.
17. Slater T.F., Cheeseman K.H., Davies M.J., Hayashi M., Sharma O.P., Nigam S., et al. Free radical scavenging properties of modulators of eicosanoid metabolism. Adv. Prostaglandin Thromboxane Leukot. Res. 1987, 17B:1098-1102.
18. Naczk M., Shahidi F. Extraction and analysis of phenolics in food. J. Chromatogr. A 2004, 1054(Oct (1-2)):95-111.
19. Waris G., Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog. 2006, 5:14.
20. Agrawal K., Kaur M., Bajaj P., Agrawal C., Pathania O.P. Metaplastic carcinomas of the breast (light microscopic and immunohistochemical features). Indian J. Cancer 2001, 38(Dec (2-4)):80-84.
21. Yilma A.N., Singh S.R., Morici L., Dennis V.A. Flavonoid naringenin: a potential immunomodulator for Chlamydia trachomatis inflammation. Mediators Inflamm. 2013, 2013:102457.
22. Zhang P., Lin R., Yang G., Zhang J., Zhou L., Liu T. Solubility of naringenin in ethanol and water mixtures. J. Chem. Eng. Data. 2013, 58(9):2402-2404.
23. Kanaze F.I., Bounartzi M.I., Georgarakis M., Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur. J. Clin. Nutr. 2007, 61(4):472-477.
24. Yun C.H., Okerholm R.A., Guengerich F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A (4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. Biol. Fate Chem. 1993, 21(Jun (3)):403-409.
25. Guengerich F.P. Cytochromes P450 drugs, and diseases. Mol. Interv. 2003, 3(Jun (4)):194-204.
26. Fasinu P., Choonara Y.E., Khan R.A., Du Toit L.C., Kumar P.K., Ndesendo V.M. Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability. J. Pharm. Sci. 2013, 102(2):541-555.
27. Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit juice-drug interactions. 1998. Br. J. Clin. Pharmacol. 2004, 58(Dec (7)):S831-S840. (discussion S841-3).
28. Li R-F., Feng Y-Q., Chen J-H., Ge L-T., Xiao S-Y., Zuo X-L. Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes. Exp. Ther. Med. 2015, 9(3):697-706.
29. Jang K-I., Lee H.G. Stability of chitosan nanoparticles for l-ascorbic acid during heat treatment in aqueous solution. J. Agric. Food Chem. 2008, 56(Mar (6)):1936-1941.
30. Singleton L.C., Connor T.H. An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs. Oncol. Nurs. Forum 1999, 26(Oct (9)):1491-1496.
31. Zhang L., Kosaraju S.L. Biopolymeric delivery system for controlled release of polyphenolic antioxidants. Eur. Polym. J. 2007, 43(7):2956-2966.
32. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 1987, 84(Dec (24)):9265-9269.
33. Schmucki R., De Blois S., Bouchard A., Domon G. Spatial and temporal dynamics of hedgerows in three agricultural landscapes of southern Quebec, Canada. Environ. Manage. 2002, 30(Nov (5)):651-664.
34. Halliwell B., Gutteridge J.M. Formation of thiobarbituric-acid-reactive substance from deoxyribose in the presence of iron salts: the role of superoxide and hydroxyl radicals. FEBS Lett. 1981, 128(Jun (2)):347-352.
35. Marks D.C., Belov L., Davey M.W., Davey R.A., Kidman A.D. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res. 1992, 16(12):1165-1173.
36. Konecsni K., Low N.H., Nickerson M.T. Chitosan-tripolyphosphate submicron particles as the carrier of entrapped rutin. Food Chem. 2012, 134(Oct (4)):1775-1779.
37. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70(Jan (1-2)):1-20. (Off. J. Control. Release Soc.).
38. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 2004, 57(1):1-8. (Off. J. Arbeitsgemeinschaft Für Pharm Verfahrenstechnik EV).
39. Janes K.A., Fresneau M.P., Marazuela A., Fabra A., Alonso M.J. Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 2001, 73(Jun (2-3)):255-267. (Off. J. Control. Release Soc.).
40. Mitra M., Misra R., Harilal A., Sahoo S.K., Krishnakumar S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis. 2011, 17:2724-2737.
41. Konan-Kouakou Y.N., Boch R., Gurny R., Allémann E. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J. Control. Release 2005, 103(Mar (1)):83-91. (Off. J. Control. Release Soc.).
42. Ulański P., Rosiak J. Preliminary studies on radiation-induced changes in chitosan. Int. J. Radiat. Appl. Instrum., C: Radiat. Phys. Chem. 1992, 39(1):53-57.
43. Ko J.A., Park H.J., Hwang S.J., Park J.B., Lee J.S. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int. J. Pharm. 2002, 249(Dec (1-2)):165-174.
44. Shu X.Z., Zhu K.J. Controlled drug release properties of ionically cross-linked chitosan beads: the influence of anion structure. Int. J. Pharm. 2002, 233(Feb (1-2)):217-225.
45. Zhang H., Huang Q., Huang Z., Liu T., Li Y. Preparation and physicochemical properties of chitosan broadleaf holly leaf nanoparticles. Int. J. Pharm. 2015, 479(Feb (1)):212-218.
46. Hu B., Pan C., Sun Y., Hou Z., Ye H., Hu B., et al. Optimization of fabrication parameters to produce chitosan-tripolyphosphate nanoparticles for delivery of tea catechins. J. Agric. Food Chem. 2008, 56(Aug (16)):7451-7458.
47. Zhang H., Alsarra I.A., Neau S.H. An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int. J. Pharm. 2002, 239(Jun (1-2)):197-205.
48. Sulfikkarali N., Krishnakumar N., Manoharan S., Nirmal R.M. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis. Pathol. Oncol. Res. POR 2013, 19(Apr (2)):287-296.
49. Cerutti P., Ghosh R., Oya Y., Amstad P. The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ. Health Perspect. 1994, 102(Dec (Suppl. 10)):123-129.
50. Feng G., Kaplowitz N. Mechanism of staurosporine-induced apoptosis in murine hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282(5):G825-G834.
51. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43(Jun (2)):109-142.
52. Khan N., Bharali D.J., Adhami V.M., Siddiqui I.A., Cui H., Shabana S.M., et al. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014, 35(2):415-423.
53. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65(Dec (1-2)):55-63.
54. Ahmadian S., Barar J., Saei A.A., Fakhree M.A.A., Omidi Y. Cellular toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J. Vis. Exp. JoVE 2009, 26:1191-1192.